1.
Clinics (Sao Paulo)
; 67 Suppl 1: 125-9, 2012.
Article
in English
| MEDLINE
| ID: mdl-22584717
ABSTRACT
The recent availability of molecular targeted therapies leads to a reconsideration of the treatment strategy for patients with distant metastases from medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Medullary/drug therapy , Piperidines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Thyroid Neoplasms/drug therapy , Antineoplastic Agents/adverse effects , Carcinoma, Medullary/pathology , Carcinoma, Neuroendocrine , Clinical Trials as Topic/standards , Humans , Molecular Targeted Therapy , Patient Selection , Piperidines/adverse effects , Quinazolines/adverse effects , Thyroid Neoplasms/secondary
2.
Clinics
; Clinics;67(supl.1): 125-129, 2012. tab
Article
in English
| LILACS
| ID: lil-623142
ABSTRACT
The recent availability of molecular targeted therapies leads to a reconsideration of the treatment strategy for patients with distant metastases from medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered.